Virax Biolabs Group stock is among today’s top performers. What’s fueling VRAX momentum?Virax Subsidiary Receives Crucial CertificiationsVirax Biolabs said that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, a risk management company based in the United Kingdom. ISO 13485:2016 covers the design and development of immunological assay components and kits, including a ...

Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation Accessibility StatementSkip Navigation LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 Fe ...

Core Viewpoint - Virax Biolabs Group Limited (VRAX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - The Zacks rating upgrade for Virax Biolabs reflects an improvement in its earnings outlook, which is expected to positively impact its stock price [4][6]. Impact of Earnings Estimate Revisions - There is a strong correlation between earnings estimate revisions and near-term stock movements, making it beneficial for investors to track these revisions [7]. - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks, with a historical average annual return of +25% for Zacks Rank 1 stocks since 1988 [8]. Specific Earnings Data for Virax Biolabs - For the fiscal year ending March 2026, Virax Biolabs is expected to earn -$0.40 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 60.4% over the past three months [9]. Zacks Rating System Overview - The Zacks rating system maintains a balanced distribution of "buy" and "sell" ratings across over 4,000 stocks, with only the top 20% receiving a "Strong Buy" or "Buy" rating [10][11]. - The upgrade of Virax Biolabs to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11].

Core Viewpoint - Virax Biolabs Group Limited has successfully closed a private placement raising $5 million, which will extend its cash runway into the first half of 2028, supporting ongoing regulatory studies related to long COVID and other immune-related conditions [1][3]. Financial Details - The company sold 12,500,000 ordinary shares and preferred investment options at a combined price of $0.3999 per pre-funded warrant, with an exercise price of $0.0001 per share for the pre-funded warrants [2]. - The preferred investment options have an exercise price of $0.40 per ordinary share and are exercisable for five years from the effective date of the Initial Registration Statement [2]. Use of Proceeds - The net proceeds from the offering will be utilized for general working capital needs, allowing the company to continue its studies on post-acute sequelae of COVID-19 and post-acute infection syndrome [3]. Regulatory Compliance - The securities offered were part of a private placement exempt from registration under the Securities Act of 1933, and the company plans to file an Initial Registration Statement with the SEC for the resale of the ordinary shares [4]. Investment Options Adjustment - The company has agreed to reduce the exercise price of its outstanding Series A and Series B Preferred Investment Options from $2.934 to $0.40 per share and extend their term to the fifth anniversary of the effective date of the Initial Registration Statement [5]. Company Overview - Virax Biolabs Group Limited focuses on the detection of immune responses and diagnosis of viral diseases, developing T cell-based test technologies aimed at addressing chronic conditions linked to immune dysregulation, such as Long COVID [7].

Core Viewpoint - Virax Biolabs Group Limited has announced a private placement for the purchase and sale of 12,500,000 ordinary shares at a price of $0.40 per share, aiming to raise gross proceeds of $5 million for working capital and corporate purposes [1] Group 1: Private Placement Details - The private placement includes ordinary shares and preferred investment options to purchase an additional 12,500,000 ordinary shares [1] - The exercise price for the preferred investment options is set at $0.40 per ordinary share, exercisable immediately for five years [1] - H.C. Wainwright & Co. is the exclusive placement agent for this offering [1] Group 2: Financial Implications - The expected gross proceeds from the private placement are $5 million, before deducting fees and expenses [1] - The company plans to use the net proceeds for working capital and other general corporate purposes [1] Group 3: Regulatory and Compliance Aspects - The securities involved in this transaction are not registered under the Securities Act of 1933 and cannot be reoffered or resold in the U.S. without proper registration or exemption [1] - Virax has agreed to file an initial registration statement with the SEC for the resale of the ordinary shares issued to investors [1] Group 4: Company Overview - Virax Biolabs Group Limited focuses on immunology research and diagnostics, particularly in the detection of immune responses to viral diseases [1] - The company is developing T cell-based test technologies aimed at diagnosing conditions like Long COVID and other chronic immune-related issues [1]

Core Viewpoint - Virax Biolabs is positioned for significant advancements in its proprietary diagnostic technology for post-acute infection syndromes (PAIS), including Long COVID, with a focus on achieving key clinical and operational milestones in 2026 [1][2] Company Developments - The company completed recruitment for its first UK clinical study (VRX-002) ahead of schedule, with initial data expected in Q2 2026 [1] - A second UK trial (VRX-003) in PAIS has been fully enrolled [1] - A clinical collaboration with Emory University has been established to support U.S. regulatory and commercial plans for Long COVID [1] - The ImmuneSelect research-use-only (RUO) portfolio is being developed to generate near-term revenue [1] Financial Position - As of September 30, 2025, the company held approximately $3.3 million in cash, with total assets of $5.7 million and no long-term debt, resulting in shareholders' equity of roughly $5.1 million [2] - The market capitalization is approximately $1.7 million, indicating that the market currently assigns limited value to the company's clinical programs and intellectual property [2] Strategic Priorities for 2026 - The primary focus is to deliver high-quality clinical data from the UK PAIS study and initiate U.S. clinical work with Emory University [2] - The company aims to expand its ImmuneSelect RUO portfolio and explore collaborations in vaccine response and oncology [2] - Continued engagement with regulatory bodies in both the UK and U.S. is planned to support the development of ViraxImmune™ [2]

Financial Performance - Revenue for the six months ended September 30, 2025, was $1,608, compared to $4,953 for the same period in 2024, indicating a decrease of approximately 68.7%[5] - Net loss for the six months ended September 30, 2025, was $2,343,273, a reduction from a net loss of $2,756,564 in the same period of 2024, reflecting an improvement of about 15%[5] - The company reported a comprehensive loss of $2,510,851 for the six months ended September 30, 2025, compared to a comprehensive loss of $2,675,803 in the same period of 2024, indicating a decrease of approximately 6.1%[5] - For the six months ended September 30, 2025, the loss attributable to Virax was $2,338,771, a decrease from $2,756,427 in the same period of 2024, representing a 15.2% improvement[80] - Basic and diluted loss per share for the six months ended September 30, 2025, was $(0.49), compared to $(0.89) for the same period in 2024, indicating a 45% reduction in loss per share[80] Assets and Liabilities - Total assets decreased from $6,426,903 as of March 31, 2025, to $5,715,015 as of September 30, 2025, representing a decline of approximately 11%[3] - The accumulated deficit increased from $24,589,244 as of March 31, 2025, to $26,928,015 as of September 30, 2025, an increase of about 9.5%[3] - Cash at the end of the period decreased to $3,345,464 from $4,228,944 at the beginning of the period, a decline of about 20.9%[7] - As of September 30, 2025, the Company had a cash balance of $3,345,464 and current liabilities of $365,473, raising substantial doubt about its ability to continue as a going concern[14] - Current accounts payable and accrued liabilities decreased to $103,523 as of September 30, 2025, from $250,170 as of March 31, 2025, a reduction of 58.7%[87] Operating Expenses - Total operating expenses decreased from $2,872,417 in the six months ended September 30, 2024, to $2,586,762 in the same period of 2025, a reduction of approximately 10%[5] - Research and Development expenses increased significantly from $726,412 in 2024 to $1,379,745 in 2025, representing an increase of approximately 90%[5] - The Company expects to continue generating operating losses in the foreseeable future due to research and development activities and corporate overhead[17] Cash Flow and Financing - The Company reported a net decrease in cash of $883,480 for the six months ended September 30, 2025[14] - The company issued 2,201,476 shares for cash, raising $2,070,706 during the six months ended September 30, 2025[6] - The Company plans to fund its cash flow needs through current cash on hand and future debt and/or equity financings, but there is no assurance that sufficient funding will be available[15][16] - The company aims to manage its capital resources to ensure financial strength and maximize financial flexibility, primarily through the sale of ordinary shares[123] Revenue Recognition - The Company recognizes revenues upon the transfer of control of promised products, net of any taxes collected from customers[30] - 100% of the revenues for the six months ended September 30, 2025, were derived from the Company's research-use-only test kits associated with ViraxImmune[75] - The decrease in revenue is attributed to the Company's increasing focus on the ViraxImmune platform[75] Development and Research - The company is focused on developing T cell in vitro diagnostics and immune profiling, particularly in the area of post-acute infection syndromes (PAIS)[9] - The Company is developing ViraxImmune™, a T cell-based assay for immunology profiling, currently in clinical studies for conditions like long COVID and ME/CFS[10] - The Company is also developing the ImmuneSelect RUO portfolio, which includes peptide pools and immune-profiling reagents, intended for research use only[11] Stock and Options - The company issued stock options to purchase 214,500 shares at an average price of $0.88, with a fair value of $184,041 for the six months ended September 30, 2025[110] - As of September 30, 2025, there were 471,250 stock options outstanding, with 174,910 options vested and exercisable[112] - The company had 6,543,432 ordinary shares issued and outstanding as of September 30, 2025[105] - The company sold 2,201,476 shares at an average price of $0.9729 for gross proceeds of $2,141,816, resulting in net proceeds of $2,070,706 after offering costs[104] Tax and Credits - The company received $273,594 in research and development tax credits from HMRC for the six months ended September 30, 2025[82] - Total VAT receivable as of September 30, 2025, was $174,968, significantly up from $30,654 as of March 31, 2025[81] Other Financial Information - The Company has no financial instruments measured at fair value on a recurring basis as of September 30, 2025[65] - There were no impairment losses recognized for the six months ended September 30, 2025[48] - The estimated useful lives for laboratory equipment, computer equipment, and capitalized software are 5 years, 3 years, and 3 years, respectively[47] - The Company recognizes deferred tax assets only if it is probable that future taxable profit will be available to utilize those temporary differences and losses[44] - The Company does not have any expected credit losses on financial assets measured at amortized cost as of September 30, 2025[66] - Management does not consider there to be any significant judgments or estimates in the revenue recognition for the six months ended September 30, 2025[76]

Core Insights - Virax Biolabs Group Limited has signed a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies on ViraxImmune™, focusing on immune profiling in individuals with post-viral syndromes, particularly long COVID [1][2][3] - The collaboration aims to generate clinical data that will support regulatory submissions and potential commercial rollout of ViraxImmune™ [2][3] - The partnership is part of Virax's strategy to prepare for a pre-submission meeting with the FDA to discuss the regulatory pathway for ViraxImmune™ in PASC [3][4] Company Overview - Virax Biolabs is an innovative biotechnology company focused on immune response detection and diagnostics, particularly in viral diseases [5] - The company is developing T cell-based test technologies aimed at providing an immunology profiling platform, which is crucial for diagnosing post-viral syndromes like long COVID [5] Collaboration Significance - Partnering with Emory University, a leading institution in immunology and clinical research, is seen as a critical step in validating ViraxImmune™ in real-world patient populations [4][7] - The collaboration is expected to advance Virax's U.S. market entry strategy and create long-term value for shareholders [4]

Core Viewpoint - Virax Biolabs Group Limited has appointed Dr. Iain Miller as an Independent Director to its Board, effective July 29, 2025, succeeding Yair Erez, who is stepping down to pursue other professional opportunities [1][2]. Group 1: Appointment Details - Dr. Miller brings over 30 years of leadership experience in the diagnostics and MedTech sectors, having held senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital [3]. - He has founded and led four MedTech companies, including Presymptom Health, where he developed InfectiClear®, a novel diagnostic for infectious diseases [3][4]. - Dr. Miller holds a PhD in BioEngineering, an MBA, and a BSc in Physics & Electronics, and has published extensively on diagnostic innovation [4]. Group 2: Strategic Importance - The CEO of Virax, James Foster, emphasized that Dr. Miller's leadership and expertise will be crucial as the company advances its immune profiling platform and progresses towards IVD development and market entry [5]. - Dr. Miller expressed excitement about joining Virax at a time of strategic focus, highlighting the potential of the immune profiling platform to enhance monitoring of chronic and post-viral conditions [5]. Group 3: Company Focus - Virax Biolabs is focused on the detection of immune responses and diagnosis of viral diseases, currently developing T-Cell-based test technologies aimed at providing an immunology profiling platform [6]. - The company’s T-Cell testing is particularly relevant for diagnosing post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation [6].

Core Points - Virax Biolabs Group Limited has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share [1][2] - The company has a compliance period of 180 calendar days, until January 12, 2026, to regain compliance [3] - If the closing bid price reaches at least $1.00 for 10 consecutive business days during this period, Nasdaq will confirm compliance [3] - The notification does not lead to immediate delisting, and shares will continue to trade under the symbol "VRAX" [4] Company Overview - Virax Biolabs Group Limited is focused on the detection of immune responses and diagnosis of viral diseases [4] - The company is developing T-Cell-based test technologies aimed at providing an immunology profiling platform [4] - T-Cell testing is particularly effective for diagnosing post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation [4]